Glenmark Life Sciences Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: January 17, 2025, 11:47 pm

Market Cap	13,316 Cr.
Current Price	1,084
High / Low	1,335/666
Stock P/E	31.4
Book Value	207
Dividend Yield	2.07 %
ROCE	28.1 %
ROE	21.1 %
Face Value	2.00
PEG Ratio	-0.86

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Glenmark Life Sciences Ltd

Competitors of Glenmark Life Sciences Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
MPS Pharmaa Ltd	7.27 Cr.	3.80	4.33/3.05		0.80	0.00 %	9.15 %	34.9 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	50.4 Cr.	67.9	94.9/30.8	17.1	11.9	0.00 %	9.72 %	3.44 %	10.0
Gujarat Inject (Kerala) Ltd	41.3 Cr.	28.2	29.0/8.74	42.2	6.64	0.00 %	2.65 %	2.08 %	10.0
Godavari Drugs Ltd	68.2 Cr.	90.5	155/81.2	11.0	55.4	0.00 %	14.4 %	15.5 %	10.0
Industry Average	17,201.67 Cr	1,062.38		42.63	185.19	0.37%	16.18%	16.43%	6.27

All Competitor Stocks of Glenmark Life Sciences Ltd

Quarterly Result

Metric	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Sales	562	522	514	490	509	541	621	578	595	573	537	589	507
Expenses	394	376	372	343	366	395	415	385	428	400	395	429	373
Operating Profit	167	146	142	147	144	145	206	193	167	173	141	159	134
OPM %	30%	28%	28%	30%	28%	27%	33%	33%	28%	30%	26%	27%	27%
Other Income	2	4	5	9	10	7	3	2	5	2	3	5	9
Interest	7	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	10	10	10	10	10	11	12	13	13	13	15	14	15
Profit before tax	153	140	138	146	144	141	198	182	159	161	130	150	127
Tax %	24%	26%	28%	26%	26%	26%	26%	26%	25%	26%	24%	26%	25%
Net Profit	115	104	99	109	107	105	146	135	119	119	98	111	95
EPS in Rs	9.40	8.46	8.07	8.87	8.72	8.57	11.95	11.05	9.69	9.69	7.99	9.10	7.78

Last Updated: November 6, 2024, 6:39 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: September 23, 2024, 2:22 pm

Metric	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	0	886	1,537	1,885	2,123	2,161	2,283	2,293
Expenses	0	638	1,064	1,294	1,506	1,518	1,608	1,653
Operating Profit	-0	248	473	592	617	643	675	641
OPM %	-4%	28%	31%	31%	29%	30%	30%	28%
Other Income	0	-0	11	0	14	28	11	16
Interest	0	1	34	88	28	1	2	2
Depreciation	0	19	29	33	38	42	53	55
Profit before tax	-0	228	421	471	565	629	631	600
Tax %	4,200%	14%	26%	25%	26%	26%	25%
Net Profit	-0	196	313	352	419	467	471	447
EPS in Rs	-430.00	997.86	1,597.37	358.74	34.17	38.11	38.43	36.47
Dividend Payout %	0%	0%	0%	0%	61%	110%	59%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	59.69%	12.46%	19.03%	11.46%	0.86%
Change in YoY Net Profit Growth (%)	0.00%	-47.23%	6.57%	-7.58%	-10.60%

Glenmark Life Sciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2019-2020 to 2023-2024.

No data available for the compounded sales growth chart.

Balance Sheet

Last Updated: November 14, 2024, 3:30 pm

Month	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	0.01	2	2	2	25	25	25	25
Reserves	-1	86	400	751	2,030	2,114	2,308	2,514
Borrowings	0	0	0	0	3	19	17	16
Other Liabilities	1	1,387	1,324	1,244	414	545	501	530
Total Liabilities	0	1,475	1,726	1,997	2,471	2,702	2,850	3,085
Fixed Assets	0	456	546	573	590	781	805	821
CWIP	0	80	11	14	97	62	106	141
Investments	0	0	0	0	0	0	0	0
Other Assets	0	939	1,169	1,410	1,784	1,860	1,939	2,122
Total Assets	0	1,475	1,726	1,997	2,471	2,702	2,850	3,085

Reserves and Borrowings Chart

No data available for this post.

Free Cash Flow

Month	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	0.00	248.00	473.00	592.00	614.00	624.00	658.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	44	185	152	120	116	136	122
Inventory Days	162	441	227	214	185	224	251
Days Payable	41	201	111	92	110	158	139
Cash Conversion Cycle	165	424	268	241	190	202	235
Working Capital Days	-2,059	-186	-37	12	150	177	188
ROCE %		529%	186%	97%	42%	30%	28%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters	82.85%	82.85%	82.85%	82.85%	82.85%	82.85%	82.85%	82.85%	82.85%	82.85%	82.85%	75.00%
FIIs	8.32%	8.12%	7.58%	6.04%	4.45%	3.28%	3.27%	4.39%	4.57%	5.01%	4.81%	7.85%
DIIs	0.47%	0.56%	0.79%	0.79%	0.08%	0.00%	0.58%	0.64%	0.74%	1.41%	1.57%	4.16%
Public	8.36%	8.47%	8.78%	10.31%	12.62%	13.86%	13.30%	12.13%	11.84%	10.73%	10.76%	12.99%
No. of Shareholders	2,53,726	2,38,578	2,33,538	2,32,203	2,25,730	2,22,866	2,08,267	1,98,764	1,85,531	1,56,183	1,49,396	1,43,960

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
Old Bridge Focused Equity Fund	168,754	2.54	14.99	20,000	2025-02-23	743.77%
Nippon India Nifty Smallcap 250 Index Fund	28,442	0.15	2.53	20,000	2025-02-23	42.21%
Navi Aggressive Hybrid Fund	24,100	1.94	2.14	20,000	2025-02-23	20.5%
Navi Flexi Cap Fund	20,000	0.64	1.78	20,000	2025-02-23	0%
Navi Large & Midcap Fund - Regular Plan	20,000	0.55	1.78	20,000	2025-02-23	0%
Motilal Oswal Nifty Smallcap 250 Index Fund	12,970	0.15	1.15	20,000	2025-02-23	-35.15%
Motilal Oswal Nifty 500 Index Fund	3,194	0.01	0.28	20,000	2025-02-23	-84.03%
Motilal Oswal Nifty Smallcap 250 ETF	736	0.15	0.07	20,000	2025-02-23	-96.32%
Motilal Oswal BSE Healthcare ETF	263	0.16	0.02	20,000	2025-02-23	-98.69%
Motilal Oswal Nifty 500 ETF	108	0.01	0.01	20,000	2025-02-23	-99.46%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	2.00	2.00	2.00	2.00	10.00
Basic EPS (Rs.)	38.43	38.11	35.63	32.61	1597.37
Diluted EPS (Rs.)	38.38	38.11	35.63	32.61	1597.37
Cash EPS (Rs.)	42.79	41.55	37.27	392.83	1747.28
Book Value[Excl.RevalReserv]/Share (Rs.)	190.35	174.51	167.66	768.11	2049.45
Book Value[Incl.RevalReserv]/Share (Rs.)	190.35	174.51	167.66	768.11	2049.45
Dividend / Share (Rs.)	22.50	21.00	21.00	0.00	0.00
Revenue From Operations / Share (Rs.)	186.35	176.39	173.29	1923.64	7843.43
PBDIT / Share (Rs.)	56.01	54.78	51.48	603.96	2469.13
PBIT / Share (Rs.)	51.65	51.35	48.39	569.89	2319.30
PBT / Share (Rs.)	51.52	51.30	46.11	480.56	2148.30
Net Profit / Share (Rs.)	38.43	38.11	34.17	358.76	1597.44
PBDIT Margin (%)	30.05	31.05	29.70	31.39	31.48
PBIT Margin (%)	27.71	29.11	27.92	29.62	29.56
PBT Margin (%)	27.64	29.08	26.60	24.98	27.38
Net Profit Margin (%)	20.62	21.60	19.72	18.64	20.36
Return on Networth / Equity (%)	20.18	21.83	20.38	46.70	77.94
Return on Capital Employeed (%)	26.24	28.62	28.40	72.00	108.71
Return On Assets (%)	16.51	17.28	16.94	17.60	18.14
Asset Turnover Ratio (%)	0.82	0.83	0.95	1.01	0.96
Current Ratio (X)	4.37	3.67	4.60	1.15	0.88
Quick Ratio (X)	2.85	2.47	3.25	0.72	0.57
Inventory Turnover Ratio (X)	1.67	1.96	1.95	2.11	1.71
Dividend Payout Ratio (NP) (%)	58.54	82.65	30.72	0.00	0.00
Dividend Payout Ratio (CP) (%)	52.57	75.81	28.17	0.00	0.00
Earning Retention Ratio (%)	41.46	17.35	69.28	0.00	0.00
Cash Earning Retention Ratio (%)	47.43	24.19	71.83	0.00	0.00
Interest Coverage Ratio (X)	443.91	1227.15	22.56	6.76	14.44
Interest Coverage Ratio (Post Tax) (X)	305.58	854.68	15.97	5.02	10.34
Enterprise Value (Cr.)	9197.77	4488.68	5111.73	0.00	0.00
EV / Net Operating Revenue (X)	4.03	2.08	2.41	0.00	0.00
EV / EBITDA (X)	13.40	6.69	8.10	0.00	0.00
MarketCap / Net Operating Revenue (X)	4.16	2.22	2.65	0.00	0.00
Retention Ratios (%)	41.45	17.34	69.27	0.00	0.00
Price / BV (X)	4.07	2.24	2.74	0.00	0.00
Price / Net Operating Revenue (X)	4.16	2.22	2.65	0.00	0.00
EarningsYield	0.04	0.09	0.07	0.00	0.00

After reviewing the key financial ratios for Glenmark Life Sciences Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 2.00.
For Basic EPS (Rs.), as of Mar 24, the value is 38.43. This value is within the healthy range. It has increased from 38.11 (Mar 23) to 38.43, marking an increase of 0.32.
For Diluted EPS (Rs.), as of Mar 24, the value is 38.38. This value is within the healthy range. It has increased from 38.11 (Mar 23) to 38.38, marking an increase of 0.27.
For Cash EPS (Rs.), as of Mar 24, the value is 42.79. This value is within the healthy range. It has increased from 41.55 (Mar 23) to 42.79, marking an increase of 1.24.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 190.35. It has increased from 174.51 (Mar 23) to 190.35, marking an increase of 15.84.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 190.35. It has increased from 174.51 (Mar 23) to 190.35, marking an increase of 15.84.
For Dividend / Share (Rs.), as of Mar 24, the value is 22.50. This value exceeds the healthy maximum of 3. It has increased from 21.00 (Mar 23) to 22.50, marking an increase of 1.50.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 186.35. It has increased from 176.39 (Mar 23) to 186.35, marking an increase of 9.96.
For PBDIT / Share (Rs.), as of Mar 24, the value is 56.01. This value is within the healthy range. It has increased from 54.78 (Mar 23) to 56.01, marking an increase of 1.23.
For PBIT / Share (Rs.), as of Mar 24, the value is 51.65. This value is within the healthy range. It has increased from 51.35 (Mar 23) to 51.65, marking an increase of 0.30.
For PBT / Share (Rs.), as of Mar 24, the value is 51.52. This value is within the healthy range. It has increased from 51.30 (Mar 23) to 51.52, marking an increase of 0.22.
For Net Profit / Share (Rs.), as of Mar 24, the value is 38.43. This value is within the healthy range. It has increased from 38.11 (Mar 23) to 38.43, marking an increase of 0.32.
For PBDIT Margin (%), as of Mar 24, the value is 30.05. This value is within the healthy range. It has decreased from 31.05 (Mar 23) to 30.05, marking a decrease of 1.00.
For PBIT Margin (%), as of Mar 24, the value is 27.71. This value exceeds the healthy maximum of 20. It has decreased from 29.11 (Mar 23) to 27.71, marking a decrease of 1.40.
For PBT Margin (%), as of Mar 24, the value is 27.64. This value is within the healthy range. It has decreased from 29.08 (Mar 23) to 27.64, marking a decrease of 1.44.
For Net Profit Margin (%), as of Mar 24, the value is 20.62. This value exceeds the healthy maximum of 10. It has decreased from 21.60 (Mar 23) to 20.62, marking a decrease of 0.98.
For Return on Networth / Equity (%), as of Mar 24, the value is 20.18. This value is within the healthy range. It has decreased from 21.83 (Mar 23) to 20.18, marking a decrease of 1.65.
For Return on Capital Employeed (%), as of Mar 24, the value is 26.24. This value is within the healthy range. It has decreased from 28.62 (Mar 23) to 26.24, marking a decrease of 2.38.
For Return On Assets (%), as of Mar 24, the value is 16.51. This value is within the healthy range. It has decreased from 17.28 (Mar 23) to 16.51, marking a decrease of 0.77.
For Asset Turnover Ratio (%), as of Mar 24, the value is 0.82. It has decreased from 0.83 (Mar 23) to 0.82, marking a decrease of 0.01.
For Current Ratio (X), as of Mar 24, the value is 4.37. This value exceeds the healthy maximum of 3. It has increased from 3.67 (Mar 23) to 4.37, marking an increase of 0.70.
For Quick Ratio (X), as of Mar 24, the value is 2.85. This value exceeds the healthy maximum of 2. It has increased from 2.47 (Mar 23) to 2.85, marking an increase of 0.38.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.67. This value is below the healthy minimum of 4. It has decreased from 1.96 (Mar 23) to 1.67, marking a decrease of 0.29.
For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 58.54. This value exceeds the healthy maximum of 50. It has decreased from 82.65 (Mar 23) to 58.54, marking a decrease of 24.11.
For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 52.57. This value exceeds the healthy maximum of 50. It has decreased from 75.81 (Mar 23) to 52.57, marking a decrease of 23.24.
For Earning Retention Ratio (%), as of Mar 24, the value is 41.46. This value is within the healthy range. It has increased from 17.35 (Mar 23) to 41.46, marking an increase of 24.11.
For Cash Earning Retention Ratio (%), as of Mar 24, the value is 47.43. This value is within the healthy range. It has increased from 24.19 (Mar 23) to 47.43, marking an increase of 23.24.
For Interest Coverage Ratio (X), as of Mar 24, the value is 443.91. This value is within the healthy range. It has decreased from 1,227.15 (Mar 23) to 443.91, marking a decrease of 783.24.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 305.58. This value is within the healthy range. It has decreased from 854.68 (Mar 23) to 305.58, marking a decrease of 549.10.
For Enterprise Value (Cr.), as of Mar 24, the value is 9,197.77. It has increased from 4,488.68 (Mar 23) to 9,197.77, marking an increase of 4,709.09.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 4.03. This value exceeds the healthy maximum of 3. It has increased from 2.08 (Mar 23) to 4.03, marking an increase of 1.95.
For EV / EBITDA (X), as of Mar 24, the value is 13.40. This value is within the healthy range. It has increased from 6.69 (Mar 23) to 13.40, marking an increase of 6.71.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 4.16. This value exceeds the healthy maximum of 3. It has increased from 2.22 (Mar 23) to 4.16, marking an increase of 1.94.
For Retention Ratios (%), as of Mar 24, the value is 41.45. This value is within the healthy range. It has increased from 17.34 (Mar 23) to 41.45, marking an increase of 24.11.
For Price / BV (X), as of Mar 24, the value is 4.07. This value exceeds the healthy maximum of 3. It has increased from 2.24 (Mar 23) to 4.07, marking an increase of 1.83.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 4.16. This value exceeds the healthy maximum of 3. It has increased from 2.22 (Mar 23) to 4.16, marking an increase of 1.94.
For EarningsYield, as of Mar 24, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.09 (Mar 23) to 0.04, marking a decrease of 0.05.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation. If you have any questions or need more detailed insights, please feel free to reach out.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Glenmark Life Sciences Ltd as of February 24, 2025 is: ₹1,119.88

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of February 24, 2025, Glenmark Life Sciences Ltd is Undervalued by 3.31% compared to the current share price ₹1,084.00

Intrinsic Value of Glenmark Life Sciences Ltd as of February 24, 2025 is: 708.93

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of February 24, 2025, Glenmark Life Sciences Ltd is Overvalued by 34.60% compared to the current share price ₹1,084.00

Last 5 Year EPS CAGR: -36.70%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 130.29%, which is a positive sign. The company has higher reserves (1,275.25 cr) compared to borrowings (6.88 cr), indicating strong financial stability. The company has shown consistent growth in sales (112.00 cr) and profit (443.13 cr) over the years.	The stock has a high average Working Capital Days of 43.14, which may not be favorable. The stock has a high average Cash Conversion Cycle of 246.43, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Glenmark Life Sciences Ltd:
1. Net Profit Margin: 20.62%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 26.24% (Industry Average ROCE: 16.18%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 20.18% (Industry Average ROE: 16.43%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 305.58
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 2.85
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 31.4 (Industry average Stock P/E: 42.63)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

No data availabale for About the Company

INDUSTRY	ADDRESS	CONTACT
Industry not found	Address not found	Contact not found

Management Data not Available

FAQ

What is the latest intrinsic value of Glenmark Life Sciences Ltd?

The latest intrinsic value of Glenmark Life Sciences Ltd as on 27 January 2025 is ₹1119.88, which is 3.31% higher than the current market price of ₹1,084.00. The stock has a market capitalization of 13,316 Cr. and recorded a high/low of 1,335/666 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹2,514 Cr and total liabilities of 3,085 Cr.

What is the Market Cap of Glenmark Life Sciences Ltd?

The Market Cap of Glenmark Life Sciences Ltd is 13,316 Cr..

What is the current Stock Price of Glenmark Life Sciences Ltd as on 27 January 2025?

The current stock price of Glenmark Life Sciences Ltd as on 27 January 2025 is 1,084.

What is the High / Low of Glenmark Life Sciences Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Glenmark Life Sciences Ltd stocks is 1,335/666.

What is the Stock P/E of Glenmark Life Sciences Ltd?

The Stock P/E of Glenmark Life Sciences Ltd is 31.4.

What is the Book Value of Glenmark Life Sciences Ltd?

The Book Value of Glenmark Life Sciences Ltd is 207.

What is the Dividend Yield of Glenmark Life Sciences Ltd?

The Dividend Yield of Glenmark Life Sciences Ltd is 2.07 %.

What is the ROCE of Glenmark Life Sciences Ltd?

The ROCE of Glenmark Life Sciences Ltd is 28.1 %.

What is the ROE of Glenmark Life Sciences Ltd?

The ROE of Glenmark Life Sciences Ltd is 21.1 %.

What is the Face Value of Glenmark Life Sciences Ltd?

The Face Value of Glenmark Life Sciences Ltd is 2.00.